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Keppner L, Heinrichs M, Rieckmann M, Demengeot J, Frantz
S, Hofmann U, Ramos G. Antibodies aggravate the development of
ischemic heart failure. Am J Physiol Heart Circ Physiol 315: H1358–
H1367, 2018. First published August 10, 2018; doi:10.1152/ajpheart.
00144.2018.—Heart-specific antibodies have been widely associated
with myocardial infarction (MI). However, it remains unclear whether
autoantibodies mediate disease progression or are a byproduct of
cardiac injury. To disambiguate the role of immunoglobulins in MI,
we characterized the development of ischemic heart failure in agam-
maglobulinemic mice (AID/S/). Although these animals can
produce functional B cells, they cannot synthesize secretory IgM
(S/) or perform Ig class switching (AID/), leading to complete
antibody deficiency. Agammaglobulinemia did not affect overall
post-MI survival but resulted in a significant reduction in infarct size.
Echocardiographic analyses showed that, compared with wild-type
infarcted control mice, AID/S/ mice exhibited improved car-
diac function and reduced remodeling on day 56 post-MI. These
differences remained significant even after animals with matched
infarct sizes were compared. Infarcted AID/S/ mice also
showed reduced myocardial expression levels of transcripts known to
promote adverse remodeling, such as matrix metalloproteinase-9,
collagen type I a1, collagen type III a1, and IL-6. An unbiased
screening of the heart reactivity potential in the plasma of wild-type
MI animals revealed the presence of antibodies that target the myo-
cardial scar and collagenase-sensitive epitopes. Moreover, we found
that IgG accumulated within the scar tissues of infarcted mice and
remained in close proximity with cells expressing Fc receptors
(CD16/32), suggesting the existence of an in situ IgG-Fc receptor
axis. Collectively, our study results confirm that antibodies contribute
to ischemic heart failure progression and provide novel insights into
the mechanisms underlying this phenomenon.
NEW & NOTEWORTHY Our study sheds some light on the
long-standing debate over the relevance of autoantibodies in heart
failure and might stimulate future research in the field. The observa-
tion of extracellular matrix-specific antibodies and the detection of
Fc receptor-expressing cells within the scar provide novel insights
into the mechanisms by which antibodies may contribute to adverse
remodeling.
antibodies; heart failure; myocardial infarction; remodeling
INTRODUCTION
Myocardial infarction (MI) is the most common cause of
death worldwide, accounting for 20% of all deaths in Europe
(9). It is characterized by cardiac cell death after persistent
ischemia. Adult hearts have poor regenerative potential. Thus,
the repair mechanisms that occur in the infarcted myocardium
cannot reestablish the status quo ante, and the viable myocar-
dium that was lost during an acute MI is subsequently replaced
by collagenous scar tissue. This situation often leads to adverse
cardiac remodeling and chronic heart failure (HF) in later
stages. Ischemic HF is a severe condition associated with high
mortality rates and characterized by ventricular wall thinning,
cardiac dilation, and severe contractile impairment (10).
Immunological phenomena have a deep influence on
post-MI inflammation, healing, and remodeling processes.
Macrophages and neutrophils readily invade the injured heart,
where they promote the clearance of necrotic debris and
contribute to in situ inflammation and tissue repair (24). MI can
also induce specific immune responses because B and T lym-
phocytes also infiltrate the injured myocardium (15, 16, 20,
26). However, how adaptive immune mechanisms contribute to
the progression of HF remains largely elusive.
Heart-specific antibodies have been widely detected in the
plasma of rodents and patients with MI and ischemic HF (e.g.,
see Refs. 4–9, 17, and 27). The cardiac antigens targeted by
these autoantibodies fall within three major categories: sarco-
mere proteins (e.g., anti-myosin, actin, and troponin) (27, 28),
cardiac receptors (e.g., anti-1-adrenergic receptors) (30), and
damage-associated epitopes (13). However, whether these au-
toantibodies should be perceived as disease-modifying agents
or as simple biomarkers of cardiac injury remains under dis-
pute.
Elevated myosin-specific antibody titers have previously
been correlated with a poorer prognosis in patients with MI
(27). However, Dangas et al. (6) further observed higher
anti-myosin antibody titers in patients with larger infarct sizes
and suggested that this could simply indicate large infarct
sizes. Furthermore, the finding that myosin distribution is
confined to the cytoplasmic space and, therefore, is not acces-
sible to antibody targeting has led many authors to conclude
that myosin antibodies have little effect on disease progression.
Patients with MI and ischemic HF can also produce autoan-
tibodies targeting surface receptors, including 1-adrenergic
receptors (Adrb1), on cardiomyocytes (1, 7, 30). In principle,
this specificity seems to have higher clinical relevance because
antibodies targeting epitopes on the second extracellular loop
of the Adrb1 receptor can exert agonistic effects and thereby
modify cardiac function (30). Experimental studies have dem-
onstrated that the administration of Adrb1-specific antibodies
in rats promoted dilative cardiomyopathy (1). However, de-
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spite the meaningful mechanistic potential of this finding, these
antibodies were detected in only a small subgroup of patients
with ischemic HF (30), and their clinical significance remains
uncertain.
Recent studies have further revealed that autoantibodies
already present in healthy subjects before the onset of cardiac
injury (termed natural autoantibodies) can recognize damage-
associated molecular patterns (DAMPs) and readily accumu-
late in wounded tissues, including ischemic hearts (13, 25, 32).
Experiments performed in the context of ischemia-reperfusion
injury showed that natural IgMs can activate the complement
cascade and fuel inflammation in ischemic tissues (13, 32).
These experimental observations confirm that IgMs play a role
in the early steps of MI. However, the causal link between
autoantibodies and late cardiac remodeling has not been estab-
lished.
In the present study, we sought to assess the development of
ischemic HF in agammaglobulinemic (AID/S/) mice
for the sake of establishing the role of autoantibodies in this
model. We found that transgenic mice lacking the capacity to
secrete Igs (though retaining a preserved B cell compartment)
present attenuated myocardial inflammation and fibrosis in
response to MI.
METHODS
Animals
Male mice aged 8–12 wk old were included in this study. Wild-
type (WT) C57Bl6/J mice were obtained from The Jackson Labora-
tory, and AID/S/ animals were originally produced by inter-
crosses of AID/ and S/ mice at the Instituto Gulbenkian de
Ciência. The double-mutant AID/ S/ mouse strain used in this
study offers a unique and original opportunity to dissect the different
roles of B cells and antibodies in the context of MI. The S/
mutation renders B cells incapable of secreting soluble IgM molecules
but has no impact on the expression of membrane IgMs (meaning that
the S/ mice can generate functional B cells). However, because B
cells can undergo Ig class switching, single-mutant S/ mice can
still exhibit normal levels of all other Ig isotopes (IgA, IgD, IGE, and
IgG). Thus, we crossed S/ mice with mice deficient in the enzyme
activation-induced cytidine deaminase (AID), which is essential for
the Ig class switching process. The resulting double-mutant animals
cannot secrete Igs of any class, but they do retain the ability to
produce functional B cells (19, 23). All strains shared the same
genetic background. All animals were housed under specific patho-
gen-free conditions with a controlled light-dark cycle and a standard
diet. The Landesverwaltungsamt Sachsen-Anhalt (Germany) Standing
Committee on Animal Research approved all of the protocols used in
this study.
Mouse Model of Permanent MI
MI was induced after left anterior descending coronary artery
(LAD) permanent ligation was performed, as previously described
(15, 31), in accordance with the guidelines for experimental models of
MI (21). In brief, the animals were kept under isoflurane anesthesia
and intubated for mechanical ventilation. They were then submitted to
thoracotomy, and the LAD was then permanently ligated (MI group).
In sham-operated animals, the procedure was identical except for the
ligation of the LAD. Body temperature was controlled during the
operation, and mice received pre- and postoperative pain management
for 3 days [buprenorphine (0.1 mg/kg body wt sc)]. All surgeries were
performed by an experienced veterinarian. Followup echo and end-
point analyses were performed on postoperative day 56 during the
chronic remodeling phase.
Echocardiography
Cardiac echocardiographic assessments were performed on a Vevo
1100 (VisualSonics, Amsterdam, The Netherlands) using a 30-MHz
probe especially developed for mice. All of the measurements were
conducted by an experienced veterinarian. In brief, mice were kept
under slight isoflurane anesthesia, and short-axis images were ac-
quired at the midpapillary and apical levels of the left ventricle (B-
and M-mode), as previously described (15, 22, 31).
End-Point Analyses
On day 56 post-MI, animals were euthanized by cervical disloca-
tion, and the blood and heart were obtained for later analyses. Blood
samples were collected directly from the heart and kept at 4°C until
plasma separation. The plasma was kept at 80°C until the assays
were performed. Hearts were readily excised under aseptic conditions
and then stored according to the requirements of downstream appli-
cations. Heart samples used for cryosectioning were stored in OCT
embedding media and immediately frozen at 80°C, whereas sam-
ples intended for RNA extraction were stored in RNAlater (Thermo
Scientific, Darmstadt, Germany) for 24 h and then at 80°C. The
samples used for protein extraction were snap frozen (see below).
Immunofluorescence
Cryosections were cut at 12 m thick, fixed in 4% formaldehyde,
blocked with carbo-free solution, and then stained with specific
antibodies according to standard protocols that were previously es-
tablished in our laboratory (29). Endogenous mouse IgG already
present in the infarcted area was detected using a polyclonal antibody
conjugated with the fluorophore Alexa 488 (dilution 1:200, Thermo
Scientific, Darmstadt, Germany). Fc- receptors (CD16/CD32) were
stained using a monoclonal antibody (dilution 1:200, clone: 93,
Biolegend). Images were acquired using an epifluorescence micro-
scope (Axioskop 2 Plus, Zeiss, Jena, Germany) coupled with a
high-resolution camera (AxioCam HRc, Zeiss) and processed using
Zen Lite (Zeiss) or ImageJ (National Institutes of Health) software.
Real-Time PCR
RNA was extracted using a tissue RNA isolation kit (Qiagen
RNeasy mini, Qiagen, Hilden, Germany). RNA concentration was
determined using a Nanodrop system, and RNA quality was assessed
based on 280/260- and 260/230-nm absorption curves. cDNA was
synthesized from 300 ng RNA using an iScript kit (Bio-Rad Labora-
tories, Munich, Germany). Quantitative expression was monitored
using a Taqman chemistry-based assay. mRNA expression levels of
the target genes were calculated after normalization to the GAPDH
housekeeping gene according to the Ct principle (where Ct is
threshold cycle). The following Taqman probes were used in this
study: IL-6 (Il6; Mm00446190_m1), transforming growth factor
(TGF)-3 (Tgfb3; Mm00436960_m1), collagen type III a1 (Col3a1;
Mm01254476_m1), collagen type I a1 (Col1a1; Mm00801666_g1),
matrix metalloproteinase (MMP)-2 (Mmp2; Mm00439498_m1),
MMP-9 (Mmp9; Mm00442991_m1), vimentin (Vim; Mm013334-
30m1), and smooth muscle actin (Acta2; Mm00725412_s1).
Immunoblot Assay to Screen for Heart-Specific Antibodies
Principle of the method. The heart reactivity potential of antibodies
produced after MI was assessed by incubating plasma obtained from
different animals with an extract of cardiac proteins (as described
below; see also Refs. 10 and 11). In this experimental setting, cardiac
proteins were separated according to their molecular weight via
SDS-PAGE and then blotted onto nitrocellulose membranes that were
then exposed to different plasma samples. A Miniblotter apparatus
with 28 parallel slots (28 SL Immunetics) was assembled on the
membranes containing heart antigens to allow the parallel testing of
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28 plasma samples against the same membrane (Fig. 5A). The anti-
bodies present in the infarcted versus sham-operated mice function as
primary antibodies in a conventional Western blot assay, and heart-
specific autoreactivity was revealed using a secondary anti-mouse
antibody conjugated to alkaline phosphatase (Fig. 5A). Plasma reac-
tivity was tested against variable heart extracts (naive hearts, myo-
cardial scars, and collagenase-digested scars) as a strategy to dissect
whether cardiac antigens were derived from cardiomyocytes or the
extracellular matrix.
Preparation of heart extracts. In the present study, we tested
plasma reactivity profiles against three distinct cardiac extracts rep-
resenting different tissue compartments. Accordingly, hearts obtained
from naïve WT mice and dissected myocardial scars obtained from
infarcted mice (d56) were each homogenized with RIPA Lysis and
Extraction Buffer supplemented with 10 l Halt Protease Inhibitor
Cocktail and 10 l Halt Phosphatase Inhibitor Cocktail (Thermo-
Fisher Scientific, Darmstadt, Germany). Samples were centrifuged (5
min, 16,110 g, 5°C), and the supernatant was then collected for
experiments. Protein concentrations were measured by the bicin-
choninic acid method (kit from Pierce, ThermoFisher) according to
the manufacturer’s instructions. Collagenase-treated scar extracts
were also prepared using collagenase type II (1 ml, 1,000 U/ml,
collagenase type II, Worthington, Troisdorf) dissolved in RPMI (VLE
RPMI 1640 medium, Merck, Darmstadt, Germany). The latter extract
was prepared to determine whether heart-specific antibodies would
target extracellular matrix elements, which are collagenase sensitive.
Extracts were then incubated in a water bath at 37°C for 30 min.
Finally, heart extracts were prepared for SDS-PAGE under reducing
conditions [in 60 mM Tris·HCl (pH 8.6), 40% glycerin, 8% SDS,
0.04% bromophenol blue, and 2% 2-mercaptoethanol while being
boiled at 95°C for 5 min].
SDS-PAGE was performed to separate cardiac antigens (100 g/
gel total protein) according to their molecular weight in Mini-
PROTEAN precast gels (4–20%, Bio-Rad Laboratories). After elec-
trophoresis, gels containing cardiac antigens were then directly blotted
onto a nitrocellulose membranes using Mini-PROTEAN Trans-Blot
Cell, as previously described (10). Membranes were blocked over-
night in PBS-0.2% Tween (Sigma-Aldrich, Munich, Germany) at 4°C
and then mounted in a Miniblotter apparatus with 28 parallel slots (28
SL Immunetics). This Miniblotter allowed for up to 28 plasma
samples to be incubated in parallel on a single membrane. Plasma
samples obtained from WT infarcted mice (56 days post-MI and
diluted 1:20 in PBS-0.2% Tween) were then incubated (room tem-
perature, 2 h) with the membrane containing cardiac protein extracts.
After the plasma was aspirated from the slots, membranes were
removed from the Miniblotter, washed, and then incubated with goat
anti-mouse IgG (-chain specific)-alkaline phosphatase antibodies for
90 min (1:400, Sigma-Aldrich). After successive washing steps in
0.2% PBS-Tween, the colorimetric reaction was developed using an
alkaline phosphatase substrate according to the manufacturer’s instruc-
tions [BCIP/NBT Color Development Substrate (5-bromo-4-chloro-3-
indolyl-phosphate/nitroblue tetrazolium; Promega, Mannheim, Ger-
many)]. The reaction was stopped by washing the membranes with
distilled water. Membranes were then scanned using a gel documen-
tation system (ImageQuant LAS400). All antibodies were used ac-
cording to the guidelines on antibody use in physiology studies (3).
Statistical Analyses
All statistical analyses were performed with GraphPad Prism 6.
All results are presented as means  SD of data obtained from
711 animals unless stated otherwise. The graphs display both group
mean values (bars) and the distribution of each individual value. For
comparisons of two groups, we used unpaired t-tests, whereas for
multiple comparisons, we performed one- and two-way ANOVA
followed by Sidak’s multiple-comparison test. The survival data are
shown as Kaplan-Meier curves, and the data were analyzed by
log-rank tests. Differences were considered significant at P  0.05.
The exact P values are reported in all graphs.
RESULTS
Ig-Deficient Mice Show Attenuated Left Ventricular
Remodeling After MI
To directly assess the contribution of antibodies to ischemic
HF progression, we studied WT and AID/S/ mice for
56 days in a permanent coronary ligature MI model. Ig defi-
ciency did not influence overall post-MI survival rates (Fig. 1,
top). However, the infarct size measured on day 56 was
significantly smaller in mice lacking antibodies than in WT
control mice (WT mice: 60.0  15.4% and AID/S/
mice: 41.36  17.9%, P 	 0.024; Fig. 1, bottom).
Left ventricular function and geometry were evaluated by
echocardiography on day 56 postoperation. Echocardiographic
images were taken at short-axis views (FS) at both the apical
and papillary levels, which represented the infarct and border
zones, respectively. No statistically significant baseline altera-
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Fig. 1. Effects of agammaglobulinemia on cumulative survival (top) and
infarct size (bottom). Wild-type (WT) and agammaglobulinemic (AID/
S/) mice were submitted to myocardial infarction (MI), and cumulative
survival was followed for 56 days. Infarct size was measured by echocar-
diography on day 56. The base graphs represent means  SD in the WT
(open circles) and agammaglobulinemic mouse (AID/S/; solid
squares) groups. Each individual value is represented by either an open
circle (WT) or an open triangle (AID/S/) in the bottom graphs.
Statistical analysis performed as shown at the bottom: t-test. The exact P
value is indicated.
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tions were observed when sham-operated WT and AID/
S/ mice were compared (except for the change in frac-
tional area at the apical level; Fig. 2A). However, Ig deficiency
had a major impact on cardiac function and geometry in
infarcted mice (Fig. 2, A–E). In WT mice, MI induced a severe
reduction in the fractional area change (FAC) and fractional
shortening (FS) at both the apical and papillary levels (P 
0.05; Fig. 2, A and B). In sharp contrast, contractility was better
preserved in infarcted Ig-deficient mice than in MI-WT mice
(P  0.05 compared with MI-WT mice). Because FAC can be
taken as a readout for systolic function, these results indicate
that Ig deficiency exerts a cardioprotective effect in the context
of MI.
Ischemic HF was also characterized by a significant increase
in end-diastolic and end-systolic areas and by thinning of the
anterior wall in WT animals (P 	 0.05; Fig. 2, C–E). In
contrast, infarcted AID/S/ mice showed no significant
post-MI cardiac dilative phenotype (P	 0.05; Fig. 2, C and D)
and no significant ventricular wall thinning, both of which are
hallmarks of adverse remodeling.
Because the distribution of infarct sizes was heterogeneous
between the genotypes, we additionally analyzed cardiac func-
tionality in a subgroup of animals exhibiting matched infarct
sizes (
30% and 60%). AID/S/ mice still exhibited
better preservation of left ventricular function and geometry
after infarct size normalization (Fig. 3). Collectively, these data
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Fig. 2. Agammaglobulinemic (AID/S/)
mice show attenuated left ventricular remodeling
after myocardial infarction (MI). Echocardio-
graphic images were obtained on day 56 at short-
axis views at both the apical and papillary levels,
which represent the infarct and border zones, re-
spectively. A and B: fractional area change and
fractional shortening (FAC and FS, respectively;
both in %). C and D: end-diastolic and end-
systolic area (EDA and ESA, respectively; both
in mm2). E: anterior wall thickness measured at
end diastole (AWT-ED; in mm). The base graphs
represent means  SD in the WT (open bars) and
AID/S/ (gray bars) groups. Each individ-
ual value is represented by either an open circle
(WT) or an open triangle (AID/S/). Sta-
tistical analysis: two-way ANOVA followed by
the Sidak post hoc test. The exact P values are
indicated.
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show that Ig deficiency is correlated with attenuated adverse
remodeling in response to MI.
Attenuated Inflammation and Extracellular Matrix Formation
in Ig-Deficient Mice
Next, we used quantitative PCR to analyze the expression
levels of genes related to inflammation, matrix proteinase
activity, and collagen production, as these are critical compo-
nents of chronic myocardial remodeling. Il6, Tgfb3, Col1a1,
Col3a1, Vim, and Acta2 transcripts were significantly upregu-
lated in response to MI in WT animals (Fig. 4). In contrast,
Ig-deficient mice that were submitted to MI showed signifi-
cantly reduced expression of Il6 and procollagen transcripts on
day 56 post-MI.
Overall, and in accordance with the echocardiographic find-
ings, these gene expression analyses indicate that Ig deficiency
results in attenuated inflammatory and fibrotic responses at
chronic stages after MI.
Myocardial Scars Are Targeted by Autoantibodies and
Harbor Cells Expressing Fc Receptors
To explore which Ig reactivities could be involved in the
progression of HF, we used an unbiased screening approach to
detect heart-specific antibodies. First, we compared the reac-
tivity profile of plasma obtained from MI versus sham-operated
mice (day 56) against naive heart extracts (Fig. 5B). As shown
in Fig. 5, heart-reactive antibodies were detected in 10 of 21
tested MI plasma samples (47%). In sharp contrast, plasma
obtained from sham-operated mice showed nearly no reactivity
against cardiac antigens (19% of animals). Overall, post-MI
antibody responses were rather mild and restricted to a limited
number of cardiac antigens (Fig. 5B).
To further dissect these findings, we tested the reactivity of
MI plasma samples against protein extracts prepared from
naive hearts, dissected scar tissues (day 56 post-MI), or colla-
genase-digested scars (shown in Fig. 5C). The rationale under-
lying this experimental design was to further dissect the source
of the antigens detected in the injured myocardium. Healthy
heart extracts are composed of proteins derived from cardiomy-
ocytes, the vasculature, resident cells, and extracellular matrix
components. In contrast, protein extracts prepared from dissected
scars were composed mostly of extracellular matrix components,
which are sensitive to collagenase digestion. All three types of
protein extracts were run in parallel on the same gel and then
transferred onto the same nitrocellulose membrane so that the
plasma reactivity profiles could be directly compared.
As shown in Fig. 5C, some infarcted animals produced
antibodies targeting epitopes that were present in viable myo-
cardium but not in dissected scars (e.g., marked by red squares
in 2; Fig. 5C). Our interpretation is that this reactivity might be
related to antigens expressed mainly by cardiomyocytes (e.g.,
contractile elements or cardiac receptors). Surprisingly, we
also detected antibodies that reacted with antigens present in
the dissected scars, which were composed mainly of extracel-
lular components (e.g., plasma 2, 6, and 9, marked by blue
squares in Fig. 5B). Moreover, these scar epitopes were also
sensitive to collagenase digestion, providing strong evidence
that they might indeed be derived from extracellular matrix
proteins. Taken together, this approach revealed that the heart-
specific antibodies produced by infarcted mice could be di-
vided into two major categories: antibodies targeting the viable
myocardium and antibodies targeting extracellular matrix com-
ponents, with the latter being a highly overlooked topic.
The profile of Igs collected from MI animals indicated that
they bear heart reactivity potential. Thus, we next sought to
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Fig. 3. Echocardiographic parameters in infarct size-
matched animals. Postmyocardial infarction (post-
MI) cardiac function and morphology were compared
in subgroups of animals exhibiting similar infarct
sizes (30–60%) according to the data shown in Fig. 1,
bottom. A and B: fractional area change and fractional
shortening (FAC and FS, respectively; both in %). C
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(ESA; D) (both in mm2). The bar graphs represent
means SD of the WT (open bars) and agammaglobu-
linemic mouse (AID/S/; gray bars) groups. Each
individual value is represented by either an open circle
(WT) or an open triangle (AID/S/). Statistical
analysis: two-way ANOVA followed by the Sidak
post hoc test. The exact P values are indicated.
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measure the presence of IgM and IgG in perfused heart
extracts. Strikingly, the amount of IgG (but not IgM) recovered
from myocardial samples was significantly higher after MI
than in healthy extract tissues (Fig. 6, top left). These findings
indicate the existence of in situ humoral immune responses in
remodeling hearts. An immunofluorescence analysis confirmed
that cardiac IgGs also accumulate in the scar zone (Fig. 6,
bottom left). We interpret these data as further supporting the
notion that in the chronic phase post-MI, autoantibodies
against myocardial/scar epitopes are induced. Finally, we also
found that these scar tissues harbored cells expressing FcR
CD16/32, which are factors that mediate the effector functions
of IgGs (Fig. 6, bottom right). The colocalization of IgG and
FcR within the scar further supports the notion that antibodies
aggravate the progression of ischemic heart failure.
DISCUSSION
The presence of heart-reactive autoantibodies in the plasma
of HF patients and rodents is a widely described phenomenon
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lular matrix formation in agammaglobulinemic
(AID/S/) mice. Expression levels of
genes related to inflammation and cardiac re-
modeling were assessed by quantitative PCR.
A: interleukin-6 (Il6). B: transforming growth
factor-3 (Tgfb3). C and D: pro-collagen-1
(Col1a1; C) and pro-collagen-3 (Col3a1; D).
E and F: matrix metalloproteinase-2 (Mmp2;
E) and matrix metalloproteinase-9 (Mmp9; F).
The base graphs show means  SD of the WT
(open bars) and AID/S/ (gray bars)
groups. G and H: vimentin (Vim) and smooth
muscle actin (Acta2). Each individual value is
represented by either an open circle (WT) or an
open triangle (AID/S/). Statistical anal-
ysis: two-way ANOVA, followed by the Sidak
post hoc test. The exact P values are indicated.
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that has been documented for many decades (e.g., see Refs.
4–9, 17, and 27). However, the functional relevance of these
autoantibodies and their putative contribution to disease pro-
gression has remained largely controversial. Moreover, in the
last decade, a series of studies have revealed that B cells are
involved in the development of post-MI inflammation (20). Yet
the question of whether B cells influence post-MI outcomes via
antibody-mediated versus independent mechanisms has re-
mained largely unresolved. This is a particularly difficult issue
to dissect because mice lacking the gene segments necessary to
build an Ig molecule also show a complete B cell deficiency
phenotype (e.g., the MT and JhT mouse strains). This is
because the expression of membrane-bound Igs is a necessary
prerequisite for B cell survival (18). In the present study, we
circumvented this limitation by performing MI experiments on
animals able to express membrane-bound Igs. Hence, these
mice could generate functional B cells but were completely
lacking the capacity to secrete soluble antibodies. Our results
indicate that antibodies critically mediate the development of
ischemic HF in mice, as Ig deficiency resulted in smaller
infarct sizes, the long-term preservation of systolic function,
and the attenuation of cardiac remodeling (i.e., ventricular
dilation and wall thinning). To the best of our knowledge, this
is the first study to use this double-mutant mouse strain in the
field of cardiology.
In the present study, we decided to focus on the role of
antibodies on chronic remodeling because previous studies
have already established the role of IgMs in mediating cardiac
injury during the early post-MI phase (4, 13). Although we
could not identify the specific contribution of IgMs and IgGs to
the phenotype described, our findings suggest that both iso-
topes might be relevant. On the one hand, the reduction in
infarct size observed in AID/S/ mice suggests that
antibodies act in the early steps after coronary ligation when
infarct expansion normally occurs as a result of secondary
damage (12). The antibody-mediated effects in these early
stages of MI require the actions of preformed Igs. Research
performed in the field of ischemia-reperfusion injury has re-
vealed that the natural IgMs that are formed before the onset of
cardiac disease can indeed recognize dying cells and fuel local
inflammation in a complement-mediated manner (4, 13). Fur-
thermore, our observation that agammaglobulinemia attenu-
ated cardiac remodeling even when animals with matched
infarct sizes were compared indicates that antibodies also
participate in the chronic stages of this disease. These long-
term effects indicate that IgGs play a role in these processes.
Fig. 5. Unbiased screening of myocardial infarction (MI)-induced heart-specific antibodies. A: experimental design. Plasma samples obtained from infarcted and
sham-operated wild-type (WT) mice (day 56) were incubated with cardiac proteins and separated according to their molecular weight by SDS-PAGE. They were
then blotted onto nitrocellulose membranes and incubated with plasma obtained from MI or sham-operated animals. Two different immunoblot settings were
tested in this study. B: plasma obtained from WT sham-operated (p1–p3, p18–p20) or infarcted (p4–17, p21–27) mice were incubated with a protein extract
prepared from a healthy heart. The images represent the results of two independent experiments (E1 and E2), and each column indicates the heart reactivity profile
of plasma obtained from different mice (p1–p27). C: MI plasma (day 56) was tested against protein extracts prepared from healthy hearts (healthy), post-MI scars
(scar), and collagenase-treated scars (collagenase). Red boxes indicate reactivity bands that targeted epitopes present in viable myocardium but not in dissected
scars. Blue boxes indicate epitopes present in dissected scars that are sensitive to collagenase degradation. The images represent the results of three independent
experiments (E1–E3), and each column indicates the heart-reactivity profile of a different sample obtained from WT infarcted animals (p1–p16).
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Fig. 6. IgG and Fc receptor- (FcR)-express-
ing cells accumulate in the scar during chronic
remodeling. Total IgM and total IgG were
detected in perfused heart extracts obtained
from healthy, myocardial infarction (MI) day
1, and MI day 56 wild-type (WT) mice (top
left). Top right and bottom: immunofluores-
cence in heart slices prepared from WT in-
farcted mice (day 56). Top right: control slices
showing tissue baseline levels of autofluores-
cence. Bottom left: IgG accumulation within
the scar. Bottom right: the remodeling scar
harbors a significant number of cells express-
ing FcR. Scar antibodies and FcR-express-
ing cells remain in close proximity within the
scar. The dashed line in the bottom images
indicates the infarct border zone.
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Small clinical trials performed in the early 2000s reported that
plasmapheresis followed by immunoadsorption of specific
IgGs improved cardiac function in patients with HF (9). Our
findings strongly support the notion that pathogenical antibod-
ies contribute to ischemic HF progression. However, we could
not determine which antibody specificities are responsible for
promoting cardiac damage and fueling adverse remodeling
after MI. Future studies will be necessary to answer these
questions, and we expect the results presented in this study
may help to revive interest in the biology of cardiac antibodies.
Most of the literature currently available on heart-specific
antibodies focuses on cardiomyocyte-derived epitopes (e.g.,
see Ref. 8). Antigens expressed on endothelial cells, fibro-
blasts, or extracellular matrix components have been highly
overlooked. Our unbiased screening approach revealed that
WT infarcted mice produce antibodies targeting collagenase-
sensitive epitopes in the scar. These findings might help to
expand the concept of “cardiac antigens” by stressing that
cardiomyocytes are not the only source of antigens in the heart.
Importantly, we observed that IgGs can accumulate within the
scar in WT infarcted mice. In addition, we found that myocar-
dial scars harbor cells expressing FcR (CD16/CD32). These
receptors interact with IgGs, and their cross-linking can lead to
the activation of various cell types (2, 3). Haudek et al. (14)
reported that cardiac fibroblasts express FcR and that their
activation mediates the differentiation of fibroblasts.
We acknowledge that the specificities and mechanisms un-
derlying the pathogenic roles of antibodies in HF progression
were not fully defined in this study. However, the associative
evidence presented here suggests a previously undescribed
antibody-FcR axis within the myocardial scar. In future work,
we might investigate whether antibody deposition in the myo-
cardial scar could lead to fibroblast activation and thereby
promote the maintenance of active remodeling processes.
Collectively, our results confirm that antibodies can mediate
the progression of ischemic HF and provide novel insights into
the mechanisms underlying this phenomenon. Our findings
may hold clinical significance, and we hope that this work will
restimulate further research in the field of heart-specific anti-
bodies.
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